News

News Subscription

Jun 14. 2017
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
Read more
Download
Jun 13. 2017
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
Read more
Download
Jun 12. 2017
Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
Read more
Download
Jun 06. 2017
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
Read more
Download
Jun 02. 2017
Basilea names new member of its Extended Management Committee
Read more
Download
Apr 28. 2017
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
Read more
Download
Apr 21. 2017
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
Read more
Download
Apr 06. 2017
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
Read more
Download
Feb 27. 2017
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
Read more
Download
Feb 20. 2017
Basilea reports solid 2016 results and expects to double product sales in 2017
Read more
Download